EXEL
Source profileExelixis
Oncology therapeutics
Company profile
CIK939767
ExchangeNASDAQ
SectorHealthcare
Tracked assets1
Pipeline assets
Zanzalintinib
Renal cell carcinoma
Phase 3Phase 3 Readout
Upcoming and past catalysts
| Company | Catalyst | Asset | Phase | Expected | Confidence | Status |
|---|---|---|---|---|---|---|
| EXEL Exelixis | STELLAR pivotal study top-line data Phase 3 Readout | Zanzalintinib | Phase 3 | 2H 2026 | half year | upcoming |
Press releases
No sample press releases for this company.
ClinicalTrials.gov studies
No linked sample studies for this company.
Change history
No sample changes yet.